Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ESPR
CUSIPN/A
Phone734-887-3903
Debt
Debt-to-Equity RatioN/A
Current Ratio6.70
Quick Ratio6.70
Price-To-Earnings
Trailing P/E Ratio-5.57
Forward P/E Ratio-6.16
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$9.34 per share
Price / Book4.16
Profitability
EPS (Most Recent Fiscal Year)($6.98)
Net Income$-166,980,000.00
Net MarginsN/A
Return on Equity-77.47%
Return on Assets-67.65%
Miscellaneous
Employees57
Outstanding Shares26,790,000
Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions
What is Esperion Therapeutics' stock symbol?
Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."
How were Esperion Therapeutics' earnings last quarter?
Esperion Therapeutics Inc (NASDAQ:ESPR) announced its quarterly earnings data on Wednesday, May, 2nd. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.56) by $0.17. During the same period last year, the company earned ($1.80) EPS. View Esperion Therapeutics' Earnings History.
When is Esperion Therapeutics' next earnings date?
What price target have analysts set for ESPR?
13 analysts have issued 1 year price targets for Esperion Therapeutics' shares. Their predictions range from $41.00 to $153.00. On average, they expect Esperion Therapeutics' share price to reach $89.0769 in the next year. View Analyst Ratings for Esperion Therapeutics.
What are Wall Street analysts saying about Esperion Therapeutics stock?
Here are some recent quotes from research analysts about Esperion Therapeutics stock:
- 1. Chardan Capital analysts commented, "We see numerous reasons for our new positive bias, including: A path forward for both BA and a BA+ezetimibe (BA+eze) fixed dose combo (FDC) has been confirmed by the FDA. A definition of statin intolerance has also been agreed on by the FDA. KOLs (e.g. Dr. Nissen) support the need for therapies for patients who are (or believe themselves to be) statin intolerant and refuse statins. CANTOS suggests BA’s high-sensitivity C-reactive protein (hsCRP) lowering effect is highly relevant for CV event reduction and outcomes. Newly-disclosed integrated phase II results suggest sound BA safety. A larger market opportunity results from a pivotal BA phase III design that includes patients “on any statin dose.” Limited use of PCSK9 inhibitors, due to pricing, opens an opportunity. Merck’s (unrated) decision not to file anacetrapib for approval further confirms oral CETP inhibitors as uninteresting assets or competitors." (12/5/2017)
- 2. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (8/23/2017)
Are investors shorting Esperion Therapeutics?
Esperion Therapeutics saw a increase in short interest in May. As of May 31st, there was short interest totalling 7,044,098 shares, an increase of 36.5% from the May 15th total of 5,159,394 shares. Based on an average daily volume of 1,113,399 shares, the days-to-cover ratio is presently 6.3 days. Currently, 29.8% of the company's shares are sold short. View Esperion Therapeutics' Current Options Chain.
Who are some of Esperion Therapeutics' key competitors?
Some companies that are related to Esperion Therapeutics include Madrigal Pharmaceuticals (MDGL), Ultragenyx Pharmaceutical (RARE), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY), HUTCHISON CHINA/S (HCM), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Supernus Pharmaceuticals (SUPN), Horizon Pharma (HZNP), Portola Pharmaceuticals (PTLA), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), The Medicines (MDCO) and OPKO Health (OPK).
Who are Esperion Therapeutics' key executives?
Esperion Therapeutics' management team includes the folowing people:
- Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 57)
- Dr. Narendra D. Lalwani, Exec. VP of R&D and COO (Age 65)
- Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 36)
- Ms. Marianne Andreach, Sr. VP of Product Planning
- Ms. Ashley Hall, Sr. VP of Global Regulatory Affairs and Policy
Has Esperion Therapeutics been receiving favorable news coverage?
Media headlines about ESPR stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Esperion Therapeutics earned a coverage optimism score of 0.06 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 43.11 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Esperion Therapeutics' major shareholders?
Esperion Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BB Biotech AG (9.01%), BlackRock Inc. (5.56%), Pinnacle Associates Ltd. (2.36%), Wasatch Advisors Inc. (2.21%), Northern Trust Corp (2.16%) and Amundi Pioneer Asset Management Inc. (1.10%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani, Nicole Vitullo, Roger S Newton and Target N V Biotech. View Institutional Ownership Trends for Esperion Therapeutics.
Which institutional investors are selling Esperion Therapeutics stock?
ESPR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Lord Abbett & CO. LLC, Wasatch Advisors Inc., Candriam Luxembourg S.C.A., New York State Common Retirement Fund, Pinnacle Associates Ltd., BlackRock Inc. and Guggenheim Capital LLC. Company insiders that have sold Esperion Therapeutics company stock in the last year include Nicole Vitullo and Roger S Newton. View Insider Buying and Selling for Esperion Therapeutics.
Which institutional investors are buying Esperion Therapeutics stock?
ESPR stock was bought by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Bellevue Group AG, JPMorgan Chase & Co., SG Americas Securities LLC, Amundi Pioneer Asset Management Inc., A.R.T. Advisors LLC, BB Biotech AG and Spark Investment Management LLC. Company insiders that have bought Esperion Therapeutics stock in the last two years include Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Target N V Biotech. View Insider Buying and Selling for Esperion Therapeutics.
How do I buy shares of Esperion Therapeutics?
Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Esperion Therapeutics' stock price today?
One share of ESPR stock can currently be purchased for approximately $38.89.
How big of a company is Esperion Therapeutics?
Esperion Therapeutics has a market capitalization of $1.12 billion. The biopharmaceutical company earns $-166,980,000.00 in net income (profit) each year or ($6.98) on an earnings per share basis. Esperion Therapeutics employs 57 workers across the globe.
How can I contact Esperion Therapeutics?
Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]
MarketBeat Community Rating for Esperion Therapeutics (ESPR)
MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe ESPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
